Huang Chen, Lu Bin, Fan Yi-Hong, Zhang Lu, Jiang Ning, Zhang Shuo, Meng Li-Na
Chen Huang, Bin Lu, Yi-Hong Fan, Lu Zhang, Ning Jiang, Shuo Zhang, Li-Na Meng, Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China.
World J Gastroenterol. 2014 Aug 21;20(31):11012-8. doi: 10.3748/wjg.v20.i31.11012.
To evaluate the effect of muscovite in preventing small bowel injury induced by nonsteroidal anti-inflammatory drugs (NSAIDs).
We recruited and screened thirty-two healthy volunteers who were randomly allocated equally into two groups: an NSAID control group, who received 75 mg slow-release diclofenac, twice daily for 14 d; and an NSAID-muscovite group, who received 3 g of muscovite in addition to the 75 mg of slow-release diclofenac, twice daily for 14 d. For gastroprotection, both groups were administered 20 mg/d of the proton pump inhibitor omeprazole. All eligible subjects underwent video capsule endoscopy (CE) prior to and 14 d after treatment.
Thirty subjects (NSAID-muscovite group, n =16; NSAID control group, n =14) finally completed the whole trail. At the baseline CE examination, no statistically significant differences between the two groups have been observed. However, after 14 d of drug treatment, a significant difference was observed in the percentage of subjects with mucosal breaks when comparing the NSAID-muscovite group with the NSAID control group. While 71.4% (10/14) of subjects in the NSAID control group had at least one mucosal break, co-administration of muscovite in the NSAID-muscovite group reduced the rate to 31.3% (5/16) (P = 0.028). Moreover, higher number of mucosal breaks was found in the NSAID control group vs that in the NSAID-muscovite group (P < 0.05).
Muscovite co-therapy reduced the incidence of small intestinal injury after 14 d of diclofenac administration.
评估白云母预防非甾体抗炎药（NSAIDs）所致小肠损伤的效果。
招募并筛选32名健康志愿者，将其随机均分为两组：NSAID对照组，每日2次，每次服用75 mg双氯芬酸缓释片，共14天；NSAID-白云母组，除每日2次，每次服用75 mg双氯芬酸缓释片外，还服用3 g白云母，共14天。为进行胃保护，两组均给予每日20 mg的质子泵抑制剂奥美拉唑。所有符合条件的受试者在治疗前和治疗14天后均接受了视频胶囊内镜检查（CE）。
30名受试者（NSAID-白云母组，n = 16；NSAID对照组，n = 14）最终完成了整个试验。在基线CE检查时，两组之间未观察到统计学上的显著差异。然而，在药物治疗14天后，比较NSAID-白云母组和NSAID对照组时，观察到黏膜破损受试者百分比存在显著差异。NSAID对照组中71.4%（10/14）的受试者至少有一处黏膜破损，而NSAID-白云母组中白云母与双氯芬酸联合使用使这一比例降至31.3%（5/16）（P = 0.028）。此外，NSAID对照组的黏膜破损数量高于NSAID-白云母组（P < 0.05）。
在服用双氯芬酸14天后，白云母联合治疗降低了小肠损伤的发生率。
